Drugs / Avtozma
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Avtozma | — | 2025-02-14 | europa.eu ↗ |
| Approved | US (FDA) | AVTOZMA | — | 2025-01-24 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT07570173 Background | May 2026 → Oct 2033 expected | B-cell acute lymphoblastic leukemia | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Avtozma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07570173 ↗ |